This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
PTEN Monoclonal Antibody (17.A)
catalog :
MA5-12278
quantity :
500 µL
price :
US 450.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
17.A
reactivity :
human, mouse
application :
western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section
citations: 26
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry; human; loading ...; fig 3c
Oktay Y, Ãœlgen E, Can Ã, Akyerli C, Yüksel Å, Erdemgil Y, et al. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Sci Rep. 2016;6:27569 pubmed publisher
  • immunohistochemistry; human; 1:50; tbl 4
Lu B, Chen Q, Zhang X, Cheng L. Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases. Diagn Pathol. 2016;11:46 pubmed publisher
  • immunohistochemistry - paraffin section; human; tbl 1
Castillo Martin M, Thin T, Collazo Lorduy A, Cordon Cardo C. Immunopathologic Assessment of PTEN Expression. Methods Mol Biol. 2016;1388:23-37 pubmed publisher
  • immunohistochemistry - paraffin section; human; loading ...; tbl 1
Siddiqui S, Akhter N, Deo S, Shukla N, Husain S. A study on promoter methylation of PTEN in sporadic breast cancer patients from North India. Breast Cancer. 2016;23:922-931 pubmed
  • immunohistochemistry; human; tbl 2
Eritja N, Santacana M, Maiques O, González Tallada X, Dolcet X, Matias Guiu X. Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model. Methods. 2015;77-78:31-40 pubmed publisher
  • immunohistochemistry; human; 1:250
Cejas P, Lopez Gomez M, Aguayo C, Madero R, Moreno Rubio J, de Castro Carpeno J, et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. Curr Cancer Drug Targets. 2012;12:124-31 pubmed
  • immunohistochemistry - paraffin section; human; 1:20
Jung Y, Joo K, Seong D, Choi Y, Kong D, Kim Y, et al. Identification of prognostic biomarkers for glioblastomas using protein expression profiling. Int J Oncol. 2012;40:1122-32 pubmed publisher
  • immunohistochemistry; human; 1:50
Skirnisdottir I, Seidal T. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:1024-31 pubmed publisher
  • immunohistochemistry; human; 1:25
Teng H, Wang H, Chen W, Chao T, Hsieh Y, Hsih C, et al. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J Surg Oncol. 2011;103:773-81 pubmed publisher
  • immunohistochemistry; mouse
  • western blot; mouse
Wang L, Liu Y, Yan Lu S, Nguyen K, Schroer S, Suzuki A, et al. Deletion of Pten in pancreatic ß-cells protects against deficient ß-cell mass and function in mouse models of type 2 diabetes. Diabetes. 2010;59:3117-26 pubmed publisher
  • western blot; mouse
Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan J, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010;107:12210-5 pubmed publisher
  • immunohistochemistry; human
Sawaki M, Iwata H, Sato Y, Wada M, Toyama T, Sasaki E, et al. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Breast. 2010;19:370-6 pubmed publisher
  • immunohistochemistry; human; 1:50
Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol. 2010;88:150-5 pubmed publisher
  • immunohistochemistry; human; 1:20
Gazzola A, Bertuzzi C, Agostinelli C, Righi S, Pileri S, Piccaluga P. Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2009;94:1036-7 pubmed publisher
  • immunohistochemistry; human
Tokyol C, Aktepe F, Hüsniye Dilek F, Yilmazer M. Comparison of placental PTEN and beta1 integrin expression in early spontaneous abortion, early and late normal pregnancy. Ups J Med Sci. 2008;113:235-42 pubmed
  • immunohistochemistry; human; 1:100
Volante M, Saviozzi S, Rapa I, Ceppi P, Cappia S, Calogero R, et al. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer. 2007;110:1321-8 pubmed
  • immunohistochemistry; human; 1:40
Pérez Tenorio G, Alkhori L, Olsson B, Waltersson M, Nordenskjold B, Rutqvist L, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007;13:3577-84 pubmed
  • immunohistochemistry; human; 1:50
Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Ciris M. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007;203:153-62 pubmed
  • immunohistochemistry; human; 1:50
Osman I, Dai J, Mikhail M, Navarro D, Taneja S, Lee P, et al. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer. 2006;107:2628-36 pubmed
  • immunohistochemistry; human; 1:150
Kolasa I, Rembiszewska A, Janiec Jankowska A, Dansonka Mieszkowska A, Lewandowska A, Konopka B, et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol. 2006;103:692-7 pubmed
  • immunohistochemistry; human
Deng H, Wu R, Zhou H, Huang X, Chen Y, Liu L. Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer. World J Gastroenterol. 2006;12:1013-7 pubmed
  • immunohistochemistry; human; 1:200
Wang Y, Kristensen G, Helland A, Nesland J, Børresen Dale A, Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol. 2005;124:392-401 pubmed
Chen M, Choi S, Wen T, Chen C, Thapa N, Lee J, et al. A p53-phosphoinositide signalosome regulates nuclear AKT activation. Nat Cell Biol. 2022;24:1099-1113 pubmed publisher
Allaf A, Victoria B, Rosario R, Misztal C, Humayun Gultekin S, Dinh C, et al. WP1066 induces cell death in a schwannomatosis patient-derived schwannoma cell line. Cold Spring Harb Mol Case Stud. 2022;8: pubmed publisher
Panigrahi A, Pinder S, Chan S, Paish E, Robertson J, Ellis I. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004;204:93-100 pubmed
Maia H, Maltez A, Studart E, Athayde C, Coutinho E. Proliferation kinetics in adenomyosis during the menstrual cycle and during oral contraceptive use. Gynecol Endocrinol. 2004;18:101-6 pubmed
product information
Product Type :
Antibody
Product Name :
PTEN Monoclonal Antibody (17.A)
Catalog # :
MA5-12278
Quantity :
500 µL
Price :
US 450.00
Clonality :
Monoclonal
Host :
Mouse
Reactivity :
Human, Mouse
Applications :
Immunocytochemistry: 1:100, Immunohistochemistry (Paraffin): 1:50-1:200, Western Blot: 1:10-1:100
Species :
Human, Mouse
Clone :
17.A
Isotype :
IgM, kappa
Storage :
4° C
Description :
PTEN was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The PTEN gene is a phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. PTEN negatively regulates intracellular levels of phosphatidylinositol-3, 4, 5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. PTEN plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Also, PTEN may be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form of PTEN induces less tumor suppressive ability.
Immunogen :
Recombinant human PTEN protein
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 1:100, Immunohistochemistry (Paraffin): 1:50-1:200, Western Blot: 1:10-1:100
Aliases :
10q23del; 2310035O07Rik; A130070J02Rik; AI463227; B430203M17Rik; BZS; CWS1; DEC; GLM2; homolog of human mutated in multiple advanced cancers; MHAM; mitochondrial phosphatase and tensin protein alpha; mitochondrial PTENalpha; Mmac; MMAC1; MMAC1 phosphatase and tensin homolog deleted on chromosome 10; mutated in multiple advanced cancers 1; Phosphatase and tensin homolog; phosphatase and tensin homolog (mutated in multiple advanced cancers 1); phosphatase and tensin homolog deleted on chromosome ten; phosphatase and tensin-like protein; phosphatidylinositol 3; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; phosphatidylinositol-3; phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; protein tyrosine phosphatase and tensin-like protein; PTEN; pten tumor suppressor; PTEN1; TEP1
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA